Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)
Project Number5R01CA237332-05
Contact PI/Project LeaderWEISSLEDER, MD, PHD, RALPH
Awardee OrganizationMASSACHUSETTS GENERAL HOSPITAL
Description
Abstract Text
The detection of intraductal papillary mucinous neoplasms (IPMN), precancerous lesions of the pancreas, is
rising due to the increasing use of high-resolution cross-sectional imaging. These cystic neoplasms have been
shown to evolve from low-grade dysplasia to high-grade dysplasia to invasive carcinoma and are believed to
account for 20-30% of all pancreatic cancers. The management of patients with some forms of IPMN remains
controversial because current technologies are unable to reliably distinguish between low and high risk IPMN.
There is therefore a need to develop better tools to facilitate the management of controversial lesions. The goal
of this proposal is to develop and test an ultra-sensitive DEST method for profiling circulating extracellular vesicles
(EV) shed by high risk IPMN. Specifically, we propose to i) develop and validate new marker sets relevant for IPMN
progression at unprecedented sensitivities (aim 1) and ii) expand and rigorously test the approach for point-of-care
analyses in prospectively collected clinical samples (aim 2). We hypothesize that highly sensitive EV analysis will
shed valuable light on biomarker composition in IPMN, a necessary prerequisite to identify high risk lesions and
early PDAC. The proposed DEST method has the potential to transform IPMN/early PDAC cancer research and
clinical practice.
Public Health Relevance Statement
There is an ever increasing need to develop better tools to facilitate the management of controversial cystic
pancreatic lesions detected incidentally by imaging. We propose to use a new analytical technique (DEST) to
study circulating extracellular vesicles (EV) in patients with incidentally detected intraductal papillary mucinous
neoplasms (IPMN), precancerous lesions of the pancreas. This will allow us to discover the make-up of EV in
clinical specimen, facilitate the management of controversial lesions and detect individuals with high likelihood of
malignant progression. The ultrasenstive vesicle detection method has the potential to transform early pancreatic
cancer research and clinical practice.
No Sub Projects information available for 5R01CA237332-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA237332-05
Patents
No Patents information available for 5R01CA237332-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA237332-05
Clinical Studies
No Clinical Studies information available for 5R01CA237332-05
News and More
Related News Releases
No news release information available for 5R01CA237332-05
History
No Historical information available for 5R01CA237332-05
Similar Projects
No Similar Projects information available for 5R01CA237332-05